Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated.The spike protein of BF.7 omicron variant has additional mutation R346T based on the BA.5 variant. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BF.7 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 BF.7 variant in a Biosafety Level 2 facility.Figure 1. Schematic of the eGFP Reporter in Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped LentivirusAs shown in Figure 2 in Validation Data, the Spike Omicron BF.7 pseudovirus has been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951) .Spike Mutations in BF.7 Omicron Variant:Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K

Product Specifications

Applications

Screen for neutralizing antibodies for the SARS-CoV-2 BF.7 variant in ACE2-HEK293 cells

Shipping Conditions

-80°C

Storage Conditions

Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C for up to 12 months from date of receipt. Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.

Notes

BiosafetyNone of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.Troubleshooting GuideVisitbpsbioscience.com/lentivirus-faqfor detailed troubleshooting instructions. For all further questions, please email[email protected].
Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein
MBS1025669-01 0.02 mg (E-Coli)

Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein

Ask
View Details
Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein
MBS1025669-02 0.1 mg (E-Coli)

Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein

Ask
View Details
Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein
MBS1025669-03 0.02 mg (Yeast)

Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein

Ask
View Details
Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein
MBS1025669-04 0.1 mg (Yeast)

Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein

Ask
View Details
Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein
MBS1025669-05 0.02 mg (Baculovirus)

Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein

Ask
View Details
Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein
MBS1025669-06 0.02 mg (Mammalian-Cell)

Recombinant Vaccinia virus Uncharacterized 13.6 kDa HindIII-C protein

Ask
View Details